Nevanac (Nepafenac)

Nepafenac is a prodrug that penetrates the cornea and is hydrolysed to amfenac, an active NSAID. Amfenac blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, reducing prostaglandin production in ocular tissues, which in turn diminishes inflammation and associated pain.

The dosing regimen for Nevanac is determined by the prescribing ophthalmologist. Typically, the doctor will advise the number of drops per eye and the frequency of administration based on the specific surgical procedure and the patient’s response.

Safety data for nepafenac in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nevanac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nevanac (nepafenac) is a prodrug that offers good corneal penetration and is converted to amfenac within the eye. Compared with other ophthalmic NSAIDs such as diclofenac or ketorolac, nepafenac may provide a slightly faster onset of action and a lower incidence of surface irritation, though individual response can vary.

Nevanac should be stored at room temperature, preferably below 25 °C, in its original container. Keep the bottle tightly closed, protect it from direct light and moisture, and discard any solution that appears discoloured or contaminated.

Nevanac is applied as an eye drop. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac, avoiding contact between the tip and the eye or any surface.

Serious adverse events, although rare, include corneal ulceration or epithelial defects, significant increases in intra‑ocular pressure, severe allergic reactions such as angio‑edema, and vision loss. Any sudden worsening of eye symptoms should prompt immediate medical evaluation.

Nevanac should not be used by individuals with known hypersensitivity to nepafenac or any component of the formulation, patients with active ocular infections, those with corneal ulcers or epithelial defects, and anyone advised against NSAID eye drops by their ophthalmologist.